

**Table 9A.9.2: Demographic Descriptive Statistics by Soft Tissue Cancer Type, by Age, United States, 1998-2011**

Type	Total N	Age Category (N (% in Age Group))						
		18-29	30-39	40-49	50-59	60-69	70-79	80+
Malignant Tumor, spindle cell type; Sarcoma, NOS; Spindle cell sarcoma; Undifferentiated sarcoma; Stromal sarcoma, NOS	13979	833 (6.0%)	1043 (7.5%)	1733 (12.4%)	2457 (17.6%)	2592 (18.5%)	2874 (20.6%)	2447 (17.5%)
Fibrous histiocytoma, malignant	13289	281 (2.1%)	590 (4.4%)	1312 (9.9%)	2136 (16.1%)	2640 (19.9%)	3379 (25.4%)	2951 (22.2%)
Liposarcoma Myxoid	4349	381 (8.8%)	810 (18.6%)	1082 (24.9%)	856 (19.7%)	579 (13.3%)	409 (9.4%)	232 (5.3%)
Liposarcoma, well differentiated	4304	62 (1.4%)	187 (4.3%)	604 (14%)	953 (22.1%)	1081 (25.1%)	913 (21.2%)	504 (11.7%)
Synovial sarcoma (NOS, spindle cell epithelioid cell, biphasic)	4175	1112 (26.6%)	877 (21%)	904 (21.7%)	620 (14.9%)	358 (8.6%)	207 (5.0%)	97 (2.3%)
Giant cell sarcoma	4141	89 (2.1%)	189 (4.6%)	413 (10%)	810 (19.6%)	919 (22.2%)	945 (22.8%)	776 (18.7%)
Malignant peripheral nerve sheath tumor; Neurilemmoma, malignant; MPNST with rhabdomyoblastic differentiation	3827	691 (18.1%)	680 (17.8%)	723 (18.9%)	646 (16.9%)	471 (12.3%)	376 (9.8%)	240 (6.3%)
Hemangiosarcoma	3471	92 (2.7%)	138 (4.0%)	261 (7.5%)	472 (13.6%)	684 (19.7%)	932 (26.9%)	892 (25.7%)
Liposarcoma, NOS	2876	48 (1.7%)	163 (5.7%)	380 (13.2%)	604 (21%)	639 (22.2%)	641 (22.3%)	401 (13.9%)
Dermatofibrosarcoma, NOS; Pigmented dermatofibrosarcoma protuberans	2776	459 (16.5%)	684 (24.6%)	693 (25%)	515 (18.6%)	221 (8.0%)	147 (5.3%)	57 (2.1%)
Fibromyxosarcoma	2356	204 (6.1%)	289 (8.6%)	459 (13.7%)	642 (19.1%)	664 (19.8%)	593 (17.7%)	505 (15%)
Fibrosarcoma, NOS	2102	202 (9.6%)	264 (12.6%)	366 (17.4%)	374 (17.8%)	314 (14.9%)	352 (16.7%)	230 (10.9%)
Liposarcoma Dedifferentiated	1768	16 (0.9%)	47 (2.7%)	180 (10.2%)	342 (19.3%)	452 (25.6%)	429 (24.3%)	302 (17.1%)
Liposarcoma Pleomorphic	1711	33 (1.9%)	71 (4.1%)	179 (10.5%)	342 (20%)	403 (23.6%)	428 (25%)	255 (14.9%)
Ewing sarcoma; Peripheral neuroectodermal tumor; Askin tumor; Primitive neuroectodermal tumor	1496	666 (44.5%)	309 (20.7%)	242 (16.2%)	141 (9.4%)	70 (4.7%)	49 (3.3%)	19 (1.3%)
Epithelioid sarcoma	1155	241 (20.9%)	198 (17.1%)	207 (17.9%)	195 (16.9%)	124 (10.7%)	115 (10%)	75 (6.5%)
Chondrosarcoma Myxoid	854	34 (4.0%)	93 (10.9%)	165 (19.3%)	200 (23.4%)	186 (21.8%)	114 (13.3%)	62 (7.3%)
Chondrosarcoma, NOS	581	41 (7.1%)	70 (12.0%)	82 (14.1%)	121 (20.8%)	108 (18.6%)	113 (19.4%)	46 (7.9%)
Hemangiopericytoma, malignant	566	27 (4.8%)	70 (12.4%)	100 (17.7%)	132 (23.3%)	112 (19.8%)	88 (15.5%)	37 (6.5%)
Pleomorphic rhabdomyosarcoma, adult type	566	24 (4.2%)	38 (6.7%)	69 (12.2%)	102 (18%)	134 (23.7%)	111 (19.6%)	88 (15.5%)
Osteosarcoma, NOS; Chondroblastic osteosarcoma; Fibroblastic osteosarcoma	562	49 (8.7%)	42 (7.5%)	75 (13.3%)	122 (21.7%)	112 (19.9%)	98 (17.4%)	64 (11.4%)
Myxosarcoma	558	14 (2.5%)	36 (6.5%)	88 (15.8%)	105 (18.8%)	109 (19.5%)	109 (19.5%)	97 (17.4%)
Rhabdomyosarcoma, NOS	555	130 (23.4%)	65 (11.7%)	51 (9.2%)	89 (16.0%)	80 (14.4%)	86 (15.5%)	54 (9.7%)
Liposarcoma Mixed Type	550	22 (4.0%)	72 (13.1%)	113 (20.5%)	120 (21.8%)	99 (18.0%)	79 (14.4%)	45 (8.2%)
Clear cell sarcoma, NOS (except of kidney)	542	116 (21.4%)	111 (20.5%)	105 (19.4%)	89 (16.4%)	51 (9.4%)	44 (8.1%)	26 (4.8%)
Liposarcoma Round cell	460	29 (6.3%)	94 (20.4%)	126 (27.4%)	92 (20.0%)	59 (12.8%)	42 (9.1%)	18 (3.9%)
Rhabdomyosarcoma Alveolar	384	226 (58.9%)	52 (13.5%)	40 (10.4%)	26 (6.8%)	17 (4.4%)	16 (4.2%)	7 (1.8%)
Alveolar soft part sarcoma	340	209 (61.5%)	69 (20.3%)	30 (8.8%)	20 (5.9%)	6 (1.8%)	6 (1.8%)	15 (4.5%)
Small cell sarcoma	310	78 (25.2%)	50 (16.1%)	57 (18.4%)	60 (19.4%)	31 (10.0%)	18 (5.8%)	16 (5.2%)
Solitary fibrous tumor, malignant	305	12 (3.9%)	19 (6.2%)	39 (12.8%)	64 (21.0%)	68 (22.3%)	69 (22.6%)	34 (11.1%)
Desmoplastic small round cell tumor	296	169 (57.1%)	72 (24.3%)	36 (12.2%)	9 (3.0%)	4 (1.4%)	5 (1.7%)	1 (0.3%)
Rhabdomyosarcoma Embryonal	277	107 (38.6%)	44 (15.9%)	40 (14.4%)	31 (11.2%)	28 (10.1%)	14 (5.1%)	13 (4.7%)
Epithelioid hemangioendothelioma, malignant	213	23 (10.8%)	35 (16.4%)	53 (24.9%)	43 (20.2%)	28 (13.1%)	26 (12.2%)	5 (2.3%)
Mesenchymal chondrosarcoma	134	36 (26.9%)	33 (24.6%)	20 (14.9%)	16 (11.9%)	12 (9.0%)	11 (8.2%)	6 (4.5%)
Malignant myoepithelioma	108	17 (15.7%)	20 (18.5%)	20 (18.5%)	18 (16.7%)	10 (9.3%)	11 (10.2%)	12 (11.1%)
Mesenchymoma, malignant	90	15 (16.7%)	10 (11.1%)	14 (15.6%)	15 (16.7%)	10 (11.1%)	15 (16.7%)	11 (12.2%)
Merkel cell carcinoma	79	0 (0.0%)	1 (1.3%)	9 (11.4%)	10 (12.7%)	19 (24.1%)	18 (22.8%)	22 (27.8%)
Granular cell tumor, malignant	71	8 (11.3%)	9 (12.7%)	14 (19.7%)	18 (25.4%)	15 (21.1%)	5 (7.0%)	2 (2.8%)

Source: American College of Surgeons National Cancer Data Base (NCDB).

NOTE: NCDB Adult Soft Tissue Sarcoma Data Summary

Demographic data is available on cases diagnosed from 1998 – 2011. A total of 91,163 cases were available. Mortality is only available from 44,065 cases reported 1998 – 2006. The sample size by cancer type is provided in the tables. The difference in sample size is related to excluding cases without followup data. Per NCDB, mortality data is not available for the last five years of collection (2007-2011). Also, per NCDB, cases were excluded if they had multiple cancer types. Note that this data set only included patients 18 years old and older. Data on children with cancer was not available for this analysis.

The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in this study and this report are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator and authors of this work.